BIO 11.5% 58.0¢ biome australia limited

Ann: Biome Releases First Half FY2024 Results, page-2

  1. 2,589 Posts.
    lightbulb Created with Sketch. 371
    Biome Releases First Half FY2024 Results

    ● Biome reports record half year and quarterly sales revenue (H1FY24 $6.02m;
    Q2FY24 $3.3m)
    ● FY24 revenue guidance upgraded to $12.5m in January 2024
    ● Biome signed landmark biological intellectual property agreement to
    develop and solely own multiple novel probiotic strains in December 2023
    ● Biome announced new cholesterol-lowering probiotic, Biome Cholesterol™
    Probiotic for release in H2FY24
    ● Biome successfully launched three new condition-specific live
    biotherapeutic products, Biome Dental™ Probiotic, Biome Lax™ Probiotic
    and Biome Recovery™ Probiotic in H1FY24
    ● Biome management reaffirms the company expects to achieve first positive
    monthly EBITDA by June 2024
    ● January’s launch into the European health retail channel has commenced
    with key distributor partners including CLF in the United Kingdom and
    iiHealthfoods in the Republic of Ireland
    ● Biome reports gross margin increase to 60% as at 31 December 2023
 
watchlist Created with Sketch. Add BIO (ASX) to my watchlist
(20min delay)
Last
58.0¢
Change
0.060(11.5%)
Mkt cap ! $124.7M
Open High Low Value Volume
54.0¢ 58.5¢ 53.0¢ $1.045M 1.858M

Buyers (Bids)

No. Vol. Price($)
1 2260 57.5¢
 

Sellers (Offers)

Price($) Vol. No.
58.0¢ 4539 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
BIO (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.